Summary of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings on Jun 27, 2018

June 27, 2018 - By Arnold Ferreira

Big Money Sentiment decreased to 1.19 in Q1 2018. It has change of 0.01, from 2017Q4’s 1.2. The ratio dropped due to Aerie Pharmaceuticals, Inc. positioning: 18 sold and 46 reduced. 17 funds took holdings and 59 increased holdings. Investors holded 34.86 million in 2017Q4 but now own 39.43 million shares or 13.11% more.
Alps Advsr, Colorado-based fund reported 50,556 shs. Pnc stated it has 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Granite Point Mngmt Ltd Partnership accumulated 0.13% or 25,000 shs. Bamco Inc stated it has 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Voya Inv Mngmt Llc reported 455,450 shs stake. Wellington Management Gp Limited Liability Partnership has invested 0.07% of its capital in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Dafna Capital Management Limited Liability Com has 3.5% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 132,770 shs. Suffolk Cap Mgmt Lc invested in 214,245 shs. New York-based Kazazian Asset Mngmt Limited Liability Corp has invested 1.04% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). California State Teachers Retirement has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). 25,409 were reported by Manufacturers Life Insur The. Atlantic Group Llc invested in 0% or 500 shs. Weiss Multi, a Alabama-based fund reported 45,000 shs. Axa holds 170,917 shs or 0.04% of its capital. Rhenman Asset Ab owns 0.27% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 40,000 shs.

Aerie Pharmaceuticals, Inc. registered $13.13 million net activity with 2 buys and 4 selling transactions since May 21, 2018. The insider Cagle Gerald D. bought 1,000 shs worth $50,245. 50,000 shs were sold by ANIDO VICENTE JR, worth $3.10M.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 10 are the (NASDAQ:AERI)’s analyst reports since January 2, 2018 according to StockzIntelligence Inc. On Wednesday, February 28 Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Wednesday, January 24 Canaccord Genuity maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Canaccord Genuity has “Buy” rating and $86.0 target. On Friday, February 16 H.C. Wainwright reinitiated Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. H.C. Wainwright has “Buy” rating and $78 target. On Thursday, March 29 Mizuho maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Wednesday, May 9 the rating was maintained by H.C. Wainwright with “Buy”. On Tuesday, May 8 the firm earned “Buy” rating by Cantor Fitzgerald. In Wednesday, May 9 report Mizuho maintained it with “Buy” rating and $7700 target. On Thursday, March 1 the firm has “Buy” rating given by H.C. Wainwright. On Tuesday, January 2 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Stifel Nicolaus. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

AERI is reaching $68.5 during the last trading session, after increased 0.66%.Aerie Pharmaceuticals, Inc. has volume of 105,247 shares. Since June 27, 2017 AERI has declined 8.48% and is downtrending. AERI underperformed by 21.05% the S&P 500.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is valued at $2.71 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Currently it has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

A couple more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were announced by: Businesswire.com which released on June 02, 2018 “Aerie Pharmaceuticals to Present at the NASDAQ 38”, also Benzinga.com on June 22, 2018 announced “Benzinga’s Daily Biotech Pulse: FDA Greenlights Tandem Diabetes’ Insulin Pump, More IPOs On Tap”, the next Businesswire.com is “Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel” on June 18, 2018. Gurufocus.com has article titled “Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Sold $9.3 million of Shares”.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: